Loading...

Atara Biotherapeutics Inc
NASDAQ:ATRA

Watchlist Manager
Atara Biotherapeutics Inc Logo
Atara Biotherapeutics Inc
NASDAQ:ATRA
Watchlist
Price: 2.87 USD +0.35% Market Closed
Updated: Mar 25, 2023

Intrinsic Value

ATRA's intrinsic value estimate is unreliable because it is based only on its relative value.

The intrinsic value of one ATRA stock under the Base Case scenario is 9.51 USD. Compared to the current market price of 2.87 USD, Atara Biotherapeutics Inc is Undervalued by 70%.

The Intrinsic Value is calculated as the average of the two valuation methods:

ATRA Intrinsic Value
Base Case
9.51 USD
Undervaluation 70%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

ATRA Profitability Score
Profitability Due Diligence

Atara Biotherapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

Negative 3-Year Average ROE
Negative 3-Year Average ROIC
Negative Free Cash Flow
Negative Operating Income
24/100
Profitability
Score

Atara Biotherapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

ATRA Solvency Score
Solvency Due Diligence

Atara Biotherapeutics Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Low Interest Coverage
Low Altman Z-Score
Long-Term Liabilities
Short-Term Liabilities
50/100
Solvency
Score

Atara Biotherapeutics Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Financials

Balance Sheet Decomposition
Atara Biotherapeutics Inc

Current Assets 295M
Cash & Short-Term Investments 243M
Receivables 40.2M
Other Current Assets 12M
Non-Current Assets 81.3M
PP&E 74.3M
Other Non-Current Assets 7M
Current Liabilities 78.9M
Accounts Payable 6.9M
Accrued Liabilities 63.2M
Other Current Liabilities 8.8M
Non-Current Liabilities 171M
Long-Term Debt 3.6M
Other Non-Current Liabilities 167M
Efficiency
0%
Gross Margin
-432%
Operating Margin
-359%
Net Margin
-432%
FCF Margin
Other

ATRA Capital Structure
Atara Biotherapeutics Inc

Market Capitalization 275M USD
Total Debt 3.6M USD
Minority Interest 0 USD
Preferred Equity 0 USD
Cash and Equivalents 92.9M USD
Short-Term Investments 150M USD
Enterprise Value 36.1M USD

Wall St
Price Targets

ATRA Price Targets Summary
Atara Biotherapeutics Inc

Wall Street analysts forecast ATRA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ATRA is 18.87 USD with a low forecast of 2.02 USD and a high forecast of 52.5 USD.

Lowest
Price Target
2.02 USD
30% Downside
Average
Price Target
18.87 USD
557% Upside
Highest
Price Target
52.5 USD
1 729% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

ATRA Competitors
Atara Biotherapeutics Inc

ATRA Suppliers & Customers
Atara Biotherapeutics Inc

Suppliers Map
Customers Map

Ownership

ATRA Insider Trading
Buy and sell transactions by insiders

Atara Biotherapeutics Inc insiders have only sold shares in the past 12 months.

During the last 12 months Atara Biotherapeutics Inc insiders have not bought any shares, and sold 682k USD worth of shares. The last transaction was made on Mar 25, 2023 by Touchon Pascal (President and CEO), who sold 56.9k USD worth of ATRA shares.

Sold
0-3
months
129k USD
4
3-6
months
134k USD
4
6-9
months
245k USD
4
9-12
months
174k USD
4
Bought
0-3
months
0
0 USD
3-6
months
0
0 USD
6-9
months
0
0 USD
9-12
months
0
0 USD
Cumulative Transactions Amount
Period Sold Bought Net
3 Months
129k USD
N/A
-129.1k
6 Months
263k USD
N/A
-262.9k
9 Months
508k USD
N/A
-507.7k
12 Months
682k USD
N/A
-682.1k
Purchases
13
Sales
398
No transactions found
Why is insider trading important?

Shareholder Return

ATRA Return Decomposition
Main factors of price return

Price Return Decomposition
is not available

It is impossible to break down the market cap return as the net margin from 5 years ago is negative.

What is price return decomposition?

ATRA Price
Atara Biotherapeutics Inc

1M 1M
-30%
6M 6M
-15%
1Y 1Y
-69%
3Y 3Y
-68%
5Y 5Y
-93%
Annual Price Range
2.87
52w Low
2.83
52w High
9.84
Price Metrics
Average Annual Return -15.52%
Standard Deviation of Annual Returns 29.9%
Max Drawdown -94%
Shares Statistics
Market Capitalization 275M USD
Shares Outstanding 101 990 000
Percentage of Shares Shorted 13.03%

Company Profile

Atara Biotherapeutics Inc Logo
Atara Biotherapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

275M USD

Dividend Yield

0%

Description

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company is headquartered in South San Francisco, California and currently employs 578 full-time employees. The company went IPO on 2014-10-16. The firm is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune disease. Its platform leverages the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other serious diseases through engineered chimeric antigen receptors (CARs) or T-cell receptors (TCRs). The Company’s pipeline products include Tab-cel, ATA188, ATA2271, ATA3271 and ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA188 is a T-cell immunotherapy for the treatment of multiple sclerosis.

Contact

CALIFORNIA
South San Francisco
611 Gateway Blvd Ste 900
+16502788930.0
http://www.atarabio.com/

IPO

2014-10-16

Employees

578

Officers

Pres, CEO & Director
Dr. Pascal Touchon D.V.M.
Exec. VP & CFO
Mr. Utpal Koppikar M.B.A.
Sr. VP & Gen. Counsel
Mr. K. Amar Murugan
Exec. VP and Global Head of R&D
Dr. Jakob Dupont M.D.
Chief Technical Officer
Ms. Charlene Banard
Chief Scientific Officer
Dr. Anhco Nguyen
Show More
VP of Investor Relations & Fin.
Eric Hyllengren
Head of Corp. Communications
Kerry Beth Daly
Chief People Officer
Ms. Amie Krause
Exec. VP
Mr. Joseph Newell
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one ATRA stock?

The intrinsic value of one ATRA stock under the Base Case scenario is 9.51 USD.

Is ATRA stock undervalued or overvalued?

Compared to the current market price of 2.87 USD, Atara Biotherapeutics Inc is Undervalued by 70%.